Weekly insulin jab could cut type 2 diabetes injections by 86%

For hundreds of thousands of people in Britain managing type 2 diabetes, the daily ritual of insulin injection has become a fixture of survival—a routine that shapes mornings, travels, and the simple act of being away from home. A new treatment could change that. A weekly insulin jab, approved in principle by the health authorities that decide what the NHS can offer, would cut the number of injections needed each year by 86 percent. Instead of reaching for a needle every single day, patients would need only one injection per week.

The numbers tell part of the story. Around 4.7 million people in the UK were living with diabetes in 2024-25, and roughly 90 percent of them had type 2 diabetes—the form where the body either doesn't produce enough insulin or the insulin it makes doesn't work as it should. Of those millions, about one in four takes insulin to manage their condition. For many of them, the new treatment could be transformative, though not yet available. The National Institute for Health and Care Excellence, the body responsible for deciding which medicines the NHS should fund, has already recommended it. But before patients can actually access it, another regulator—the Medicines and Healthcare products Regulatory Agency—must grant it a license. Health officials say they are waiting on that decision to understand whether the treatment can be rolled out across the NHS.

The real benefit lies not in the science alone but in who it will help most. The treatment works as well as daily insulin, according to those who have studied it. But its true power emerges when you consider the people for whom daily injections have become a genuine burden. Frailer elderly patients, people with sight loss, those with limited hand movement, people with learning disabilities—these are the groups most likely to struggle with the precision and repetition that daily injections demand. Someone who has difficulty following the steps involved, or who finds it hard to stick to a daily regime, would find a once-weekly option far more manageable. For those who rely on a carer, family member, or healthcare professional to help them inject, the reduction from seven injections a week to one represents not just convenience but a real shift in how much support they need.

Douglas Twenefour, head of clinical work at Diabetes UK, framed it in terms of dignity and autonomy. For some people, especially those with additional care needs, moving to a weekly injection could help them manage their diabetes more easily and improve their quality of life. He also emphasized something deeper: that everyone who could benefit needs to be supported by their healthcare team to make informed decisions, and that this treatment should help reduce inequities in diabetes care—the gaps that often leave the most vulnerable behind.

Helen Knight, director of medicines evaluation at Nice, echoed that concern. She said the new treatment could make a real difference to the day-to-day lives of people with type 2 diabetes, particularly those who rely on someone else to help them inject. She also acknowledged the tension that always exists in healthcare: the recommendation represents rigorous, evidence-based decision-making that strikes a balance between the benefits to patients and the best use of limited NHS funding.

The path to availability remains incomplete. Nice's recommendation applies to the NHS in England, and Wales frequently follows its guidance. But Northern Ireland reviews such recommendations through its Department of Health, and Scotland manages the process through its own Scottish Medicines Consortium. The MHRA's decision will be the gate through which this treatment must pass before any of those systems can offer it to patients. Until that happens, hundreds of thousands of people will continue their daily routine, waiting to see whether the burden might finally ease.